Search Results 191-200 of 8313 for Terminal

1. Castleman disease - Symptoms and causes - Mayo Clinic

   This rare disorder involves an overgrowth of cells in your body's lymph nodes. Treatment varies depending on how many lymph nodes are involved.

2. Identifying Posterior Circulation Candidates for Thrombectomy Using Perfusion Imaging - Mayo Clinic

   Participation eligibility · Other serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 6 months. · Pre-existing medical, ...

3. TRITON-CM: A Study To Evaluate Nucresiran In Patients With Transthyretin Amyloidosis With Cardiomyopathy - Mayo Clinic

   * Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \>300 ng/L and \<8500 ng/L; In patients with permanent or persistent atrial ...

4. A Study to Evaluate Ketamine to Treat Chronic Neuropathic Pain in Patients with Traumatic Brachial Plexus Injuries - Mayo Clinic

   C5-T1, trunks, divisions, cords, and terminal branches. Exclusion Criteria: - Patients without pain following traumatic brachial plexus injuries. - Patients ...

5. Acupuncture For The Treatment of Autonomic Dysfunction - Mayo Clinic

   Terminal illness; Active Sepsis/Bacteremia. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to ...

6. Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations - Mayo Clinic

   Treatment with experimental therapy within 5 terminal half-lives (t1/2) or 4 weeks prior to enrollment, whichever is longer. Current or planned ...

7. Spine Clinic - Anticipatory Thinking (AT) in Patient Care Scenarios

   If a patient has between 1 and 2 years of interaction, then a “terminal event” will be appended to the data. If a patient has more than 2 years of ...

8. Leukemia - Symptoms and causes - Mayo Clinic

   Leukemia is cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system. Many types of leukemia exist.

9. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure

   Terminal illness other than HF, such as malignancy, or with a life expectancy of less than 1 year as determined by the enrolling clinician-investigator.

10. A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence - Mayo Clinic

    ... terminal half-life of luspatercept based on multiple-dose pharmacokinetics [PK] data) after discontinuation of study therapy. Male subjects must: Practice ...